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Polymorphism that Increases Risk of
Docetaxel-Induced Neuropathy
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Abstract
Purpose: Discovery of SNPs that predict a patient's risk of
docetaxel-induced neuropathy would enable treatment indi-
vidualization to maximize efﬁcacy and avoid unnecessary tox-
icity. The objectives of this analysis were to discover SNPs
associated with docetaxel-induced neuropathy and mechanis-
tically validate these associations in preclinical models of drug-
induced neuropathy.
Experimental Design: A genome-wide association study
was conducted in metastatic castrate-resistant prostate cancer
patients treated with docetaxel, prednisone and randomized
to bevacizumab or placebo on CALGB 90401. SNPs were
genotyped on the Illumina HumanHap610-Quad plat-
form followed by rigorous quality control. The inference was
conducted on the cumulative dose at occurrence of grade
3þ sensory neuropathy using a cause-speciﬁc hazard model
that accounted for early treatment discontinuation. Genes
with SNPs signiﬁcantly associated with neuropathy were
knocked down in cellular and mouse models of drug-induced
neuropathy.
Results: A total of 498,081 SNPs were analyzed in 623 Cauca-
sian patients, 50 (8%) of whom experienced grade 3þ neuropathy.
The 1,000 SNPs most associated with neuropathy clustered in
relevant pathways including neuropathic pain and axonal guidance.
An SNP in VAC14 (rs875858) surpassed genome-wide signi-
ﬁcance (P ¼ 2.12  108, adjusted P ¼ 5.88  107). siRNA
knockdown of VAC14 in stem cell–derived peripheral neuronal
cells increased docetaxel sensitivity as measured by decreased neur-
ite processes (P ¼ 0.0015) and branches (P < 0.0001). Prior to
docetaxel treatment, VAC14 heterozygous mice had greater noci-
ceptive sensitivity than wild-type litter mate controls (P ¼ 0.001).
Conclusions: VAC14 should be prioritized for further valida-
tion of its potential role as a predictor of docetaxel-induced
neuropathy and biomarker for treatment individualization.
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Introduction
The taxane class includes three FDA–approved chemothera-
peutic agents, paclitaxel, docetaxel, and cabazitaxel that have
activity in a variety of solid tumors including lung, breast, ovarian,
gastric, and prostate cancers. Taxanes bind to and stabilize micro-
tubules, ultimately inhibiting the mitotic phase of cell-cycle
development (1). The taxanes and other microtubule-targeting
chemotherapeutic agents (e.g., vinca alkaloids) commonly
induce peripheral neuropathy of varying severity (2). Chemo-
therapy-induced peripheral neuropathy (CIPN) often presents as
a combination of paresthesia and dysesthesia and can progress to
irreversible loss of balance anddexteritywith continued treatment
(3). Because of the progressive nature of the toxicity and its
potential effect on long-term quality of life (4), CIPN can neces-
sitate treatment discontinuation, even in the context of active
tumor control.
Patient demographic (i.e., race and history of neuropathy) and
treatment (i.e., cumulative dose and drug exposure) factors have
been associated with CIPN (5–8), but there are currently no
effective methods for predicting CIPN risk and/or severity.
Genome-wide association studies (GWAS) of paclitaxel and vin-
cristine-induced CIPN conﬁrm that genetic variation modiﬁes
patients' risk (9–12). The discovery and validation of SNPs that
inﬂuence risk of docetaxel-induced peripheral neuropathy would
be of clinical beneﬁt, enabling identiﬁcation of high-risk patients
in whom taxane use should be avoided if possible. SNPs that
modulate risk of docetaxel-induced neuropathy have been
reported from candidate gene studies (13–15); however, no study
has taken a genome-wide approach. On the basis of the previous
success of GWAS in discovering SNPs that affect paclitaxel-
induced neuropathy, a similar analysis was conducted in a cohort
of docetaxel-treated patients to identify genetic predictors of
docetaxel-induced neuropathy.
GWAS was performed in a large, prospectively enrolled,
chemotherapy-na€ve cohort of patients with metastatic cas-
trate-resistant prostate cancer (mCRPC) who were treated with
up to 2 years of docetaxel and prednisone, with half random-
ized to concurrent bevacizumab (16). As these metastatic
patients are at high risk of early treatment discontinuation due
to disease progression and/or death, which precludes occur-
rence of neuropathy, a competing-risks adjusted statistical
model was utilized (17, 18). Following discovery of an SNP
that surpassed genome-wide signiﬁcance, pharmacogenetic
replication between the results of a previously conducted
GWAS of paclitaxel-induced neuropathy (9), and this GWAS
of docetaxel-induced neuropathy and mechanistic validation of
that gene in cellular and animal models were attempted to
determine whether genetic predictors of CIPN were similar
between the taxanes and to potentially validate clinically useful
genetic predictors of docetaxel-induced sensory peripheral
neuropathy.
Methods
Patients and toxicity
Cancer and Leukemia Group B (CALGB/Alliance) 90401 was a
double-blinded phase III trial that equally randomized men with
hormone-refractory prostate cancer to receive docetaxel and pred-
nisone with or without bevacizumab for up to 2 years (16). All
patients enrolled in the CALGB 90401 parent studywho provided
IRB-approved informed consent for a pharmacogenomic sub-
study (CALGB 60404)were eligible for this GWAS. Brieﬂy, patient
eligibility included histologically documented adenocarcinoma
of the prostate that had progressed while the patient was on
hormone deprivation therapy. Relevant exclusion criteria includ-
ed prior chemotherapy or antiangiogenesis therapy or clinically
signiﬁcant (grade 2þ) peripheral neuropathy. Toxicity data were
collected by the Alliance Statistics and Data Center at each
treatment cycle on standardized forms that mandated reporting
of grade 3þ peripheral sensory neuropathy, as deﬁned by Nation-
al Cancer Institute Common Toxicity Criteria for Adverse Events
(NCI CTCAE) version 3.0. In addition, one case was reported
as a grade 3 cranial neuropathy event described as "sensory-
facial." Only neuropathy that was considered by the clinician to
be possibly, probably, or deﬁnitely attributable to treatment, and
occurred within 30 days of docetaxel administration, was includ-
ed in the analysis.
Docetaxel treatment
All patients received 75 mg/m2 docetaxel infused over 1 hour
on day 1 of each 21-day cycle with 8-mg oral dexamethasone
12, 3, and 1 hour prior to infusion. Patients on both arms also
received 5-mg oral prednisone twice daily and were randomized
to 15 mg/kg bevacizumab or placebo by intravenous infusion
on day 1 of each cycle. Use of growth factor, aspirin, antiemetics,
and luteinizing hormone releasing hormone agonists was under
the discretion of the treating physician. Docetaxel administra-
tion was held for neutropenia (absolute neutrophil count
< 1,500 cells/mm3), and the dose was decreased in increments
of 10 mg/m2 for hepatic dysfunction, neurotoxicity, gastroin-
testinal toxicity, or febrile neutropenia. The protocol mandated
discontinuation of docetaxel treatment if the patient required
more than two docetaxel dose decreases or in the event of
speciﬁc toxicities or conﬁrmed cancer progression.
Translational Relevance
The taxanes are a class of chemotherapeutic agents that
are commonly associated with treatment-limiting peripher-
al sensory neuropathy. Genetic predictors of paclitaxel-
induced neuropathy have been discovered but little is
known about whether similar genetic factors are associated
with risk of docetaxel-induced neuropathy. Discovery of
genetic predictors of docetaxel-induced neuropathy could
inform personalized treatment decisions to maximize efﬁ-
cacy and avoid unnecessary toxicity. We conducted a
genome-wide association study in a large cohort of Cauca-
sian men with hormone-refractory prostate cancer treated
with docetaxel. One SNP in VAC14 that was signiﬁcantly
associated with docetaxel-induced neuropathy was then
mechanistically validated in cellular and animal models of
neurotoxicity. These ﬁnding suggest that distinct genetic
variants inﬂuence risk of peripheral neuropathy from pac-
litaxel and docetaxel. The genetic variant identiﬁed in this
study could be useful for understanding the mechanism of
docetaxel-induced neuropathy and may be informative for
avoiding docetaxel treatment in patients at elevated neu-
ropathy risk.
VAC14 SNP Predicts Docetaxel-Induced Neuropathy
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Genotyping
A 10-mL sample of whole blood was collected from all
patients enrolling on the pharmacogenomic substudy prior
to initiation of protocol treatment. Genotyping and genetic
quality control were similar to that previously reported in
the CALGB 40101 GWAS (9). Genotyping was performed on
the HumanHap610-Quad Genotyping BeadChip (Illumina
Inc.) at the RIKEN Center for Genomic Medicine. Genotype
data are available at dbGap (http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?study_id¼phs001002.v1.p1)
SNPs that were known indeterminate (n ¼ 4,106) or
unreliable loci (Tech Note: Inﬁnium Genotyping Data Anal-
ysis, 2007) and patients with SNP call rate < 95% were
excluded. Eigensoft version 3.0 was used to visualize genetic
ancestry for the 790 evaluable patients to identify a genetic
European population (n ¼ 623) in which the analysis was
conducted. Additional SNPs were excluded for low call rate
(<99%), low minor allele frequency (MAF; <0.05), P value
of Hardy–Weinberg distribution <1  108 or nonautoso-
mal loci, leaving 498,081 SNPs for analysis (Supplementary
Fig. S1).
Cellular sensitivity experiments
Commercially available human induced pluripotent stem
cell (iPSC)-derived peripheral neurons (Peri.4U) were pur-
chased from Axiogenesis and plated at 1  104 cells/well in
100 mL media as per manufactures' instructions. Figure 3A
illustrates the scheme for this experiment. Dharmacon Accell
technology (GE Dharmacon) was applied at 4 hours postplat-
ing using 1 mmol/L human siVAC14 SMARTpool or the non-
targeting control (NTC). Twenty-four hours later, transfection
media were exchanged for media containing 0.17% DMSO
vehicle control and either docetaxel (LKT Laboratories Inc.) or
paclitaxel (Sigma-Aldrich). The drugs were prepared in a dark-
ened hood by dissolving powder in 100% DMSO to obtain a
stock solution of 58.4 mmol/L. Stock drug was serially diluted
in media for ﬁnal dosing concentrations ranging from
10 pmol/L to 1 mmol/L, increasing by factors of 10. Control
wells were treated with 0.17% ﬁnal concentration of DMSO to
match drug treatments. After 24- or 48-hour drug treatments,
neurons were stained with 0.3 ng/mL Hoechst 33342 (Sigma-
Aldrich) and 1.5 mg/mL Calcein AM (Molecular Probes,
Life Technologies Inc.) and imaged at 10magniﬁcation using
an ImageXpress Micro imaging microscope (Molecular
Devices, LLC) at the University of Chicago Cellular Screening
Center (Chicago, IL). Neurite changes were determined by
individual cell measurements of relative total neurite out-
growth, relative number of processes, relative number of
branches, mean/median/max process length, relative cell body
area, relative straightness, and relative mean outgrowth inten-
sity. The data represent triplicate experiments making mea-
surements on more than 1,000 cells per treatment as previ-
ously described (19). Two wells of transfected cells were
collected per time point using the Cells-to-Ct kit (Ambion,
Life Technologies Inc.) and reverse-transcribed as per kit
instructions. Quantitative real-time reverse transcription
PCR (qRT-PCR) was performed using TaqMan primers (Fisher
Scientiﬁc LLC) for VAC14 (Hs00947931_m1) and compared
with human b-2-microglobulin (NM_004048.2) housekeep-
ing gene at 24, 48, and 72 hours posttransfection (as previ-
ously described; ref. 19).
Mouse sensitivity experiments
Mice bred for VAC14 heterozygosity (VAC14þ/) and VAC14
wild-type littermates (VAC14þ/þ) on C57/BL6 background were
obtained from Lois Weisman at University of Michigan (Ann
Arbor, MI) and acclimated to living conditions at University of
Maryland (Bethesda,MD; ref. 20).Mice (3–5months of age)were
randomly assigned to docetaxel or placebo treatment, with 6 to
7 mice in each treatment arm. The entire experiment was con-
ducted separately in male and female mice. Intraperitoneal
administration of 2 mg/kg docetaxel or saline vehicle was admin-
istered on days 1, 3, 5, and 7.
Behavioral testing for the development of increased mechan-
ical sensitivity took place at baseline (prior to treatment), day 5
(after two doses), day 8 (24 hours after the fourth dose), and
weekly for 3 additional assessments. Mechanical sensitivity
was measured in mice from both treatment arms simultaneous-
ly by a blinded individual using von Frey ﬁlaments, as previ-
ously described (21). Brieﬂy, mice were placed in individual
Plexiglas cubes on an elevated wire mesh platform and allowed
to acclimate for approximately 1 hour, when grooming and
exploration behaviors ended. A series of von Frey ﬁlaments
(Touch Test Sensory Evaluator Kit, myNeurolab.com), with
bending forces of 0.04 to 2.0  g, were applied to the plantar
surface of the left hind paw until the ﬁlament just bent and was
held in place for 5 seconds or until the mouse withdrew its paw.
A positive response was deﬁned as a brisk withdrawal, with or
without shaking or licking, of the hind paw during or imme-
diately upon removal of the ﬁlament application. Each ﬁlament
was tested 5 times on each hind paw starting with the 0.4-g
ﬁlament. If the 0.4-g ﬁlament elicited 3 positive responses of
5 trials, then testing continued moving downward through the
series to the 0.04-g ﬁlament and the number of withdrawals
was recorded for each ﬁlament. If the 0.4-g ﬁlament did not
elicit 3 positive responses, then testing continued moving
upward through the series to the 2.0-g ﬁlament and the number
of withdrawals was recorded for each ﬁlament. Threshold
was deﬁned as the ﬁlament with the lowest bending force that
elicited at least 3 positive responses of 5 trials.
Statistical analysis
The primary endpoint for GWAS analysis was the cumula-
tive docetaxel dose (mg/m2) at ﬁrst report of treatment-relat-
ed grade 3þ sensory peripheral neuropathy. Patients who
did not complete 2 years of therapy due to progression/death,
treatment-terminating adverse event, or any other reason were
informatively censored at the cumulative docetaxel dose
received; therefore, the statistical analysis was conducted
within a competing-risk model framework with the inference
conducted on the basis of cause-speciﬁc hazard (17, 18).
Cumulative incidence curves were constructed to visualize
the inﬂuence of each of the top three hits with neuropathy
incidence. The relationship between each SNP and neuropa-
thy was adjusted for clinical covariates with putative relevance
to neuropathy risk: diabetes (reported history of diabetes or
current diabetes treatment vs. none), age (continuous), body
mass index (BMI) (30 vs. >30 kg/m2), and treatment arm
(bevacizumab vs. placebo), regardless of whether the covar-
iate was signiﬁcantly associated with neuropathy in this
cohort.
Cross-study clinical replication of the SNP with the greatest
association with neuropathy was attempted in a cohort of
Hertz et al.
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Caucasian patients with breast cancer treated with paclitaxel on
the CALGB 40101 clinical trial (22). GWAS of the cumulative
paclitaxel dose at occurrence of grade 2þ neuropathy has previ-
ously been published (9). In addition, an SNP predictive of
paclitaxel-induced neuropathy risk (rs10771973, FGD4) dis-
covered and replicated in the CALGB 40101 GWAS was interro-
gated in the GWAS results from the docetaxel-treated Caucasian
patients on CALGB 90401 to assess whether the SNPs that
inﬂuence neuropathy risk are similar between the two taxanes.
Statistical analyses were performed by Alliance statisticians
on a database locked on August 15, 2012. All analyses were
conducted using the R [R]statistical environment version 3.1.1
(23) or higher, using extension packages survival (version 2.37-
7) (24), GenABEL (version 1.8-0; ref. 25), cmprsk (version
2.2-7; ref. 26), and interval (version 1.1-0.1; ref. 27). To search
for cumulative genetic effects, the genes that mapped to the
top 1,000 SNPs were included in a pathway enrichment anal-
ysis using the Ingenuity Pathway Analysis version 17199142
(Ingenuity Systems, Inc., www.ingenuity.com) internal algo-
rithm. Peripheral neuronal cell phenotypes (outgrowth, pro-
cesses, branching, etc.) measured after treatment with increas-
ing docetaxel and paclitaxel concentrations were compared
between VAC14 siRNA and nontargeted control siRNA using
two-way ANOVA.
Mouse mechanical sensitivity thresholds were compared prior
to docetaxel treatment between VAC14þ/þ and VAC14þ/ mice
using an interval-censored analysis with the minimum ﬁber size
inducing a response as the phenotype. The genotype groups in
the untreated mice were compared again on day 28. The same
method was used to compare sensitivity thresholds of docetaxel-
treated and untreated mice following treatment on day 8. To
assess whether VAC14þ/ mice were more sensitive to docetaxel-
induced changes in mechanical stimuli, parametric survival
regression was used to test for the effect of VAC14 by treatment
interaction on withdrawal threshold on day 8, after treatment was
completed.
Results
GWAS
The CALGB/Alliance 90401 parent study enrolled 1,050
patients, of whom 863 provided consent and registered for the
pharmacogenomics substudy CALGB 60604 (CALGB is now a
part of the Alliance for Clinical Trials in Oncology). The GWAS
included 790 patients, of whom only the 616 self-reported,
genetically deﬁned Europeans receiving treatment were included
in the analysis to minimize confounding from population sub-
structure (Supplementary Fig. S1). Demographic characteristics
for the discovery cohort including baseline covariates potentially
relevant to treatment-induced neuropathy risk are reported
in Table 1. The median age was 69 years, BMI was 29 kg/m2,
and 97 patients (16%) had a history of diabetes. Randomization
was nearly even to the bevacizumab (314 patients, 51%) and
placebo (302, 49%) arms.
The overall incidence of grade 3þ sensory neuropathy was
8.1% (50 of 616). The 566 patients who did not experience
neuropathy were classiﬁed as having either completed treat-
ment without neuropathy (3.9%) or categorized on the basis of
their reason for discontinuation: death/progression (41.1%),
non-CIPN treatment terminating adverse event (30.2%), or
withdrawal/other (16.7%; Supplementary Table S1). The risk
of neuropathy was not signiﬁcantly different in the bevacizu-
mab and placebo arms (P ¼ 0.11), which were pooled for
analysis.
GWAS analysis was performed on the cumulative docetaxel
dose (mg/m2) at ﬁrst report of treatment-induced grade 3þ
sensory peripheral neuropathy (Fig. 1). The 10 most signiﬁcant
SNPs, ranked according to the unadjusted P value for cause-
speciﬁc association with neuropathy, are listed in Table 2 with
rsID, gene annotation, and HRs before and after adjustment
(Top 1000 SNPs in Supplementary Table S2). One SNP sur-
passed Bonferroni-corrected signiﬁcance (0.05/498,022 ¼
1.004  107). This is an intronic SNP in the VAC14 gene
(rs875858, MAF ¼ 0.056), which increased neuropathy risk
[HR, 3.60; 95% conﬁdence interval (CI), 2.21–5.84; P ¼ 2.12 
108; Fig. 2A]. The second and third most strongly associated
SNPs were an intergenic SNP (rs11017056: MAF ¼ 0.223; HR,
2.61; 95% CI, 1.77–3.84; P¼ 3.84 107) and an intronic SNP
in the ATP8A2 gene (rs1326116: MAF ¼ 0.194; HR, 2.77; 95%
CI, 1.79–4.27; P ¼ 1.77  106), both of which increased
neuropathy risk (Fig. 2B and C).
The associations of all SNPs were then adjusted for treatment
arm and several clinical covariates previously reported to be
relevant to neuropathy risk including diabetes, age, and BMI. In
this particular cohort, among the clinical covariates, only
increasing age (P ¼ 0.0003) was signiﬁcantly associated with
neuropathy, although increasing BMI showed a trend toward
association (P ¼ 0.05). Covariate adjustment did not substan-
tially affect the results, although the association of VAC14
decreased below the Bonferroni-corrected signiﬁcance thresh-
old after adjustment (P ¼ 5.88  107). The top 1,000 SNPs
mapped to 240 unique genes, which were included in the
pathway analysis. The 3 most signiﬁcantly enriched pathways
in the GWAS are displayed in Supplementary Table S3. Nota-
bly, two of these enriched pathways are relevant to CIPN;
axonal guidance (P ¼ 1.20  104) and neuropathic pain
signaling in dorsal horn neurons (P ¼ 6.03  103).
Cross-GWAS pharmacogenetic replication
Because of the absence of a large cohort of docetaxel-treated
patients with prostate cancer in which to perform replication,
Table 1. Demographic data for patients included in GWAS (n ¼ 616)
Age
Median, y 68.9
Range, y 41.7–93.5
Body mass index
Median, kg/m2 29.0
Range, kg/m2 16.1–53.3
Diabetes
Yes 97 (15.8%)
No 519 (84.3%)
Treatment arm
Bevacizumab 314 (51.0%)
Placebo 302 (49.0%)
Cumulative docetaxel dose
Median, mg/m2 626
Range, mg/m2 72–2,942
ECOG performance status
0 340 (55.2%)
1 258 (41.9%)
2 18 (2.9%)
Disease type
Measurable disease 310 (50.3%)
VAC14 SNP Predicts Docetaxel-Induced Neuropathy
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and our interest in assessing whether taxanes share genetic
predictors of neuropathy risk, cross-study pharmacogenetic
replication was attempted in a cohort of paclitaxel-treated
Caucasian patients with breast cancer enrolled on CALGB
(Alliance 40101). The VAC14 SNP (rs875858) discovered in
our docetaxel-induced neuropathy GWAS was not associated
with paclitaxel-induced neuropathy in the 40101 study (P ¼
0.70; ref. 9). In addition, SNPs that were discovered in previ-
ously published GWAS of paclitaxel-induced neuropathy
[FGD4 (rs10771973): P ¼ 0.39, EPHA4 (rs17348202): P ¼
0.76, EPHA5 (rs7349683): P ¼ 0.15, intergenic (rs3125923): P
¼ 0.057, FCAMR (rs1856746): P ¼ 0.25; refs. 9, 10, 12] or
candidate SNP studies of docetaxel-induced neuropathy
[GSTP1 Ala114Val (rs1138272): P ¼ 0.98, ABCB1 1236C>T
(rs1128503): P ¼ 0.62, ABCB1 (rs4148738): P ¼ 0.90, ABCB1
3435C>T (rs1045642): P ¼ 0.80; refs. 13–15] were not asso-
ciated with docetaxel-induced neuropathy occurrence in the
CALGB 90401 patients. Finally, when comparing the top SNPs
from taxane-induced neuropathy GWAS performed within
CALGB 90401 (docetaxel) and 40101 (paclitaxel), there was
no statistical evidence that the degree of overlap was greater
than would be expected by random chance (data not shown).
Peripheral neuronal cell sensitivity
To determine the effect of VAC14 knockdown on neuronal
sensitivity to docetaxel and paclitaxel, commercially available
human iPSC-derived peripheral neurons (Peri4.U) were utilized.
At the time of image analysis, which is 24 and 48 hours after drug
treatment (48 and 72 hours posttransfection), expression of
VAC14 in neurons treated with 1 mmol/L siRNA had decreased
to 54% and 44%, respectively, as compared with control cells
treated with a nontargeting siRNA (Fig. 3B). The VAC14 siRNA
knockdown at 24 hours after docetaxel treatment did not affect
relative total outgrowth (Fig. 3C) in the peripheral neurons but
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Figure 1.
Genome-wide association results. Manhattan plot displaying the unadjusted P value for the association of cumulative docetaxel dose at grade 3þ sensory
neuropathy for all SNPs that passed quality control (n ¼ 498,022). One SNP (rs875858) surpassed the Bonferonni-corrected signiﬁcance threshold of
1.0  107.
Table 2. Ten SNPs most associated with neuropathy in GWAS
Adjusteda
rsID Chromosome Position Gene MAF P HR (95% CI) P HR
rs875858 16 69332956 VAC14 0.056 2.12E08 3.60 (2.21–5.84) 5.88E07 3.85
rs11017056 10 131720630 Intergenic 0.223 3.84E07 2.61 (1.77–3.84) 6.36E07 2.58
rs1326116 13 25273046 ATP8A2 0.194 1.77E06 2.77 (1.79–4.27) 4.57E06 2.99
rs8089250 18 4762807 Intergenic 0.175 1.83E06 2.72 (1.78–4.17) 2.51E05 2.49
rs6436559 2 226061042 KIAA1486 0.063 2.62E06 3.34 (1.95–5.71) 3.26E05 3.19
rs11840337 13 25287298 ATP8A2 0.191 3.16E06 2.71 (1.75–4.18) 9.26E06 2.90
rs1566691 5 3780179 Intergenic 0.057 3.63E06 3.64 (2.03–6.52) 4.45E05 3.41
rs1027796 11 132262880 OPCML 0.305 3.90E06 2.38 (1.62–3.48) 2.41E05 2.32
rs2213920 9 117311405 Intergenic 0.128 5.26E06 2.63 (1.70–4.06) 2.11E05 2.66
rs4438470 2 228722963 SPHKAP 0.137 5.47E06 2.71 (1.73–4.25) 7.79E05 2.47
NOTE: 95% CI around HR estimate. MAF: minor allele frequency in the 90401 Caucasian cohort.
aAdjusted for patient BMI, age, history of diabetes, and treatment arm.
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resulted in signiﬁcantly greater sensitivity to docetaxel as mea-
sured by relative number of processes (P ¼ 0.0015, Fig. 3D) and
relative number of branches (P < 0.0001, Fig. 3E) Similar effects
were found in preliminary studies of VAC14 knockdown in a
human iPSC-derived cortical neuron, iCell Neurons measured
48 hours after treatment (Cellular Dynamics International; data
not shown). In contrast, VAC14 siRNA knockdown signiﬁcantly
decreased peripheral neuronal cell sensitivity to paclitaxel
as measured by these same cellular phenotypes (all P < 0.05,
Fig. 3F–H). Other morphologic characteristics including mean
process length, mean outgrowth intensity, and relative straight-
ness were also measured for docetaxel and paclitaxel (Supple-
mentary Fig. S2). We found a decreased sensitivity to docetaxel
and paclitaxel when measuring mean process length and for
mean outgrowth intensity for paclitaxel only. There was no
difference in measurements of relative straightness (data not
shown).
Mouse mechanical sensitivity
Before receiving docetaxel treatment, VAC14þ/ heterozygous
mice were more sensitive than wild-type VAC14þ/þ mice to
mechanical stimuli using von Frey ﬁlaments (P ¼ 0.001, Supple-
mentary Fig. S3). When stratiﬁed by gender, this effect was
signiﬁcant in male mice (P ¼ 0.002) but not in female mice (P
¼ 0.16); however, there was no statistically signiﬁcant gender
interaction (P¼ 0.10). The difference in sensitivity to mechanical
stimuli between genotype groups at baseline was attenuated over
the course of the experiment in untreated mice, as there was no
evidence of a difference between these groups at the end of the
experiment (P¼ 0.23). As expected, 8 days of docetaxel treatment
increased sensitivity to mechanical stimuli compared with
untreated control mice, regardless of mouse genotype (P <
0.0001, Fig. 4). Comparing across genotype groups, there was
no difference between VAC14þ/ and VAC14þ/þ mice in doce-
taxel-induced increase in threshold sensitivity to mechanical
stimuli at day 8 (P ¼ 0.18) or day 14 (P ¼ 0.80) when the
neuropathy was at its maximum.
Discussion
GWAS in a large cohort of patients with mCRPC receiving
docetaxel treatment identiﬁed an intronic SNP (rs875858)
within VAC14 that was associated with increased neuropathy
risk (HR, 3.60). VAC14 has been directly linked to neurode-
generation in animal models (20) and linked to hereditary
neuropathy conditions in humans (28). The lack of clinical
replication in a cohort of paclitaxel-treated patients with
breast cancer is perhaps due to known differences between
the two taxanes, including neuropathy proﬁle (29). Distinct
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Figure 2.
Incidence of neuropathy by genotype for highly associated SNPs. Cumulative
incidence curve of docetaxel dose at grade 3þ neuropathy occurrence
stratiﬁed by genotype for the top three hits: A, a VAC14 intronic SNP
(rs875858). B, an intergenic SNP (rs11017056). C, an ATP8A2 intronic SNP
(rs1326116). In each case, carrying the variant allele increased neuropathy risk
compared with wild-type patients, although there were too few patients who
were homozygous for the rare VAC14 variant (n ¼ 3) to draw meaningful
conclusions in this group.
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genetic modiﬁers of cellular sensitivity to paclitaxel and doc-
etaxel have been previously reported in in vitro models (30)
and the results of cellular sensitivity experiments demonstrat-
ing that VAC14 knockdown enhances sensitivity of peripheral
neurons to docetaxel but not paclitaxel for relative number of
processes and relative branching further support this hypoth-
esis. Given the distinct genetic effects on neuronal sensitivity
to docetaxel and paclitaxel, it is conceivable that the poly-
morphisms that affect neuropathy risk also differ between the
two taxanes. This would be consistent with the lack of cross-
study replication, including the lack of association with doc-
etaxel-induced neuropathy occurrence in this analysis for SNPs
(FGD4, EPHA4, and EPHA5) that have been previously dis-
covered, and in some cases replicated, in paclitaxel-induced
neuropathy GWAS (9, 10, 12, 31). Alternatively, heterogeneity
between the patient cohorts, including differences in gender,
age, and functional status, or differences in the phenotype
(grade 2þ vs. grade 3þ), may explain the lack of replication
across the clinical GWAS. This GWAS was also not able to
replicate previously reported associations between docetaxel-
induced neuropathy and SNPs in ABCB1 (15) or GSTP1
(13, 14) reported in previous candidate SNP studies, similar
to the failure of paclitaxel GWAS to replicate associations
with candidate SNPs including CYP2C83 (32).
The mechanistic importance of VAC14 in docetaxel-induced
neuropathy was tested in two preclinical models of CIPN.
Knockdown of VAC14 in the peripheral neuronal cell model
(Peri.4U) increased sensitivity to docetaxel treatment as mea-
sured by decreased neurite number of processes and neurite
branching. Interestingly, knockdown of VAC14 seemed to
decrease cellular sensitivity to paclitaxel treatment for these
morphologic characteristics, suggesting that this gene may play
an important role in the damage to processes and branching
induced by docetaxel but not paclitaxel. A similar model of
human neuronal cell sensitivity that utilizes induced pluripo-
tent cortical neurons (iCell Neurons) has previously been used
for mechanistic validation of GWAS hits that increases risk of
paclitaxel-induced neuropathy (19, 33) and vincristine-induced
neuropathy (11). These human model systems have several
advantages over the use of rodent cell lines such as rat pheo-
chromocytoma cell lines, PC12 or NS1. One major limitation of
rodent cell lines is the required treatment with nerve growth
factor to initiate nerve outgrowth, which confounds the evalu-
ation of drug treatment effects (34–36).
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To our knowledge, this is the ﬁrst study to attempt mech-
anistic validation of a ﬁnding from a clinical GWAS in an
animal model of CIPN. The Von Frey Filament Test is a well-
established rodent model to test sensitivity to nociceptive
stimuli, as a surrogate for peripheral neuropathy, that is
commonly used for mechanistic investigation of neuropathy
(21, 37, 38). Unlike the cell experiment, VAC14 heterozygous
mice were not more sensitive than wild-type littermates to the
effect of docetaxel but were more sensitive to mechanical
stimuli prior to treatment. The enhanced sensitivity in the
heterozygous mice at baseline was attenuated over time in the
untreated cohort, in both male and female mice. It is possible
that these mice acclimate to the discomfort of the mechanical
stimuli or they may be experiencing numbness, another char-
acteristic symptom of peripheral neuropathy in taxane-treated
patients, although additional experiments would be required
to test either hypothesis. It is unclear from these ﬁndings
whether patients with VAC14 polymorphisms have subclinical
neuropathy at baseline that is expressed by treatment, as
suggested by the mouse data, or whether they are similar at
baseline and have greater neuropathy development from doc-
etaxel treatment. Subjective testing that is sensitive for sub-
clinical neuropathy, perhaps with electrophysiologic or quan-
titative sensory assessment (39), in untreated patients with
wild-type and polymorphic VAC14 may help resolve this
conundrum.
The VAC14 protein provides a scaffold for the lipid kinase
PIKfyve and its positive regulator, FIG4. These proteins reside in
a complex that is responsible for the generation of the signaling
lipids phosphatidylinositol (3,5)-bisphosphate [PI(3,5)P2] and
PI5P. These lipids are essential in multiple tissues (28). The
inability of VAC14/ homozygous mice to survive beyond 1 to
2 days after birth necessitated the use of VAC14þ/ heterozy-
gous mice (20). On autopsy VAC14/ homozygous mice
exhibit massive neurodegeneration with cell bodies in the
central and peripheral nervous system containing large
vacuoles. This neurodegeneration and vacuolization are similar
to that found in FIG4-null mice, suggesting that variation in
these genes is likely to phenocopy in humans as well as in mice
(40). A rare mutation in the FIG4 gene is known to cause a
subtype of Charcot—Marie–Tooth disease, a hereditary neu-
ropathy syndrome (41). Interestingly, the CALGB 40101 pac-
litaxel-induced neuropathy GWAS discovered and replicated an
association for an SNP in FGD4 (rs10771973), another gene
known to cause Charcot—Marie–Tooth disease (42), although
this variant was not associated with docetaxel-induced neurop-
athy in our CALGB 90401 cohort.
The SNP (rs875858) discovered in this GWAS lies within an
intron of the VAC14 gene. It is unclear what effect, if any, this
individual SNP has on VAC14 expression or activity in the
peripheral neuron. In the GTEx database, there is no association
between rs875858 and VAC14 gene expression in the tibial
nerve tissue, although the power of this analysis is limited
by the relatively small number of samples (n ¼ 256) and low
MAF (0.06) of this SNP http://www.gtexportal.org/home/eqtls/
bySnp?snpId¼rs875858&tissueName¼Nerve_Tibial. In the
larger DGN cohort (n ¼ 922), rs875858 is highly associated
with IL34 (P ¼ 4e-7) expression in whole blood. IL34 is
structurally similar to colony-stimulating factor 1 and both are
ligands of the colony-stimulating factor 1 receptor (43), which
has recently been identiﬁed as an efﬁcacious target in mouse
models of Charcot–Marie–Tooth disease (44), providing an
alternative plausible biologic mechanism for this associa-
tion. Finally, it is conceivable that this SNP is not functionally
relevant but instead is a genetic marker of a different causa-
tive SNP; however, rs875858 lies in a region of low linkage
disequilibrium.
The SNP (rs1326116) with the third strongest associa-
tion with docetaxel-induced neuropathy is an intronic poly-
morphism in the ATP8A2 gene, which encodes ATP8A2, a
P4 ATPase. The P-type ATPases are a superfamily of proteins
that translocate phospholipids between the two leaﬂets of
cellular lipid bilayers (45). Several lines of evidence link
ATP8A2 to neurologic development and function; in vitro
data that ATP8A2 overexpression enhances neurite outgrowth
(46), animal data that ATP8A2 mutations cause overt pro-
gressive neurodegeneration in Wabbler-lethal mice by dis-
rupting axonal transport and polarity (47), and case reports
of ATP8A2 mutations causing severe neurologic phenotypes
in patients (48, 49).
The three pathways most highly enriched in the GWAS
results include axonal guidance and neuropathic pain signal-
ing, both of which have obvious relevance to taxane-induced
peripheral neuropathy. Growth and maintenance of neuronal
axons require organization of microtubules into a cytoskeleton
(50). Taxanes stabilize microtubules, potentially interfering
with cytoskeletal organization leading to the overt neuropathic
symptoms reported by patients. Enrichment in a similar path-
way, axonal outgrowth, was reported in a secondary analysis of
a paclitaxel-induced neuropathy GWAS, suggesting that these
two studies are identifying similar genetic signatures (51),
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despite the lack of overlap of individual SNPs in the top 1,000
hits. Neuropathic pain is one of the characteristic clinical
manifestations of taxane-induced neuropathy, in addition to
sensory and motor components (2). Neuropathic pain signal-
ing in the dorsal horn neurons may contribute to taxane-
induced peripheral neuropathy via a higher propensity for
development of central sensitization (52).
The primary limitation of this study is the lack of avail-
ability of an independent clinical trial cohort of docetaxel-
treated patients for pharmacogenetic replication. Another lim-
itation is the reliance on the protocol-speciﬁed collection of
severe peripheral neuropathy (grade 3 or higher), rather than
systematic collection across all toxicity grades. It is possible that
some patients experienced grade 2 neuropathy without pro-
gressing to grade 3 and thus were not included as neuropathy
events in this analysis. Furthermore, ordinal analysis across all
neuropathy grades (0–4) would have brought greater statistical
power and may have identiﬁed a distinct set of SNPs that
predict neuropathy severity, similar to the paclitaxel-induced
neuropathy GWAS ﬁndings in CALGB (Alliance) 40101 (9).
The lack of grade 1 or 2 neuropathy data collection may explain
the absence of events in the patients homozygous for the
rs875858 SNP. However, 2 of these patients discontinued
docetaxel treatment quite early, after 6 (442 mg/m2) and 8
(561 mg/m2) cycles for progression and grade 3 nausea/vomit-
ing, respectively. The third patient was discontinued after 26
cycles (1,746 mg/m2) for a constellation of grade 3 toxicities
including cough, dyspnea, fatigue, febrile neutropenia, and
pneumonitis, without any documentation of peripheral neu-
ropathy during treatment. The collection of DNA and compre-
hensive baseline and outcomes data, including accurate assess-
ment of timing and severity of peripheral neuropathy, in other
large clinical cohorts will allow for independent replication of
our ﬁndings.
In conclusion, GWAS of a prospectively enrolled patient
cohort identiﬁed an SNP in VAC14 that predicts sensitivity to
docetaxel-induced peripheral neuropathy. VAC14 heterozygous
mice were subsequently shown to be more sensitive to noci-
ceptive stimuli at baseline, and peripheral neuronal cell
(Peri.4U) sensitivity to docetaxel is enhanced after VAC14
knockdown, providing mechanistic validation of the relevance
of VAC14 to docetaxel-induced neuropathy. However, the
relatively low hazard ratio of this SNP suggests that no single
variant or gene is responsible for dictating neuropathy sensi-
tivity or will be clinically useful for personalizing docetaxel
treatment. This is consistent with the multifactorial nature of
neuropathy that depends on both drug exposure and a variety
of patient factors, including age and BMI, which were associ-
ated with neuropathy occurrence in this cohort. Replication of
the inﬂuence of our top candidate SNPs on neuropathy risk in a
similar clinical trial cohort of docetaxel-treated patients with
mCRPC is of great interest to validate the role of these genes
and provide support for further investigation into this mech-
anism for chemotherapy-induced neuropathy prevention or
treatment.
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